Cargando…

COVID-19 vaccine counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study

Safety concerns about novel vaccines and necessity of COVID-19 vaccination for children, especially with underlying medical conditions, are the obstacle of COVID-19 vaccination program among pediatric population. The study was conducted to investigate the vaccine hesitancy reasons among the parents,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Mei, Zhai, Xiaowen, Chang, Hailing, Feng, Tianxing, Zhu, Yanfeng, Ma, Wenjie, Wang, Xiangshi, Ge, Yanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621049/ https://www.ncbi.nlm.nih.gov/pubmed/35759787 http://dx.doi.org/10.1080/21645515.2022.2082207

Ejemplares similares

Safety evaluation of COVID-19 vaccination during early pregnancy: A single-center prospective cohort study of Chinese pregnant women
por: Lu, Ling, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study
por: Zhang, Quanchao, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Risk factors and preventive interventions for post Covid-19 condition: systematic review
por: Pillay, Jennifer, et al.
Publicado: (2022)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Chatting with ChatGPT to learn about safety of COVID-19 vaccines – A perspective
por: Salas, Antonio, et al.
Publicado: (2023)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review
por: Gaudet, Lindsay A., et al.
Publicado: (2023)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022)

Confidence in COVID-19 vaccine effectiveness and safety and its effect on vaccine uptake in Tanzania: A community-based cross-sectional study
por: Mtei, Monica, et al.
Publicado: (2023)

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
por: Yassini, Patrick, et al.
Publicado: (2023)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022)

Factors influencing attitudes toward vaccine safety and vaccine effectiveness amongst UK healthcare professionals prior to and at the time of COVID-19 vaccine rollout: Insights from the CoPE-HCP cohort study
por: Collett, George, et al.
Publicado: (2023)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Identification of a recombinant equine coronavirus in donkey, China
por: Qi, Peng-Fei, et al.
Publicado: (2022)

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
por: Wang, Haomeng, et al.
Publicado: (2022)

Epidemiological and clinical features of SARS‐CoV‐2 infection in children during the outbreak of Omicron variant in Shanghai, March 7–31, 2022
por: Wang, Xiangshi, et al.
Publicado: (2022)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China
por: Zheng, Liwei, et al.
Publicado: (2023)

Two novel human coronavirus OC43 genotypes circulating in hospitalized children with pneumonia in China
por: Zhang, Zhaoyong, et al.
Publicado: (2022)

COVID-19 vaccine uptake, reasons, and associated factors among older adults in Shenzhen, China
por: Xie, Pei, et al.
Publicado: (2023)

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China
por: Lin, Mengna, et al.
Publicado: (2023)

Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China*
por: Cai, Jun, et al.
Publicado: (2022)

Parents’ willingness to pay for their children’s COVID-19 vaccine in Taiwan, China: A cross-sectional study
por: Huang, Chun-Lian, et al.
Publicado: (2023)

COVID-19 vaccination in people living with HIV and AIDS (PLWHA) in China: A cross-sectional study
por: Lv, Xuan, et al.
Publicado: (2023)

Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey
por: Qin, Shijie, et al.
Publicado: (2023)

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
por: Wang, Miao, et al.
Publicado: (2022)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

The unreversible reduced but persistent activated NK and CD8(+) T cells in severe/critical COVID-19 during omicron pandemic in China
por: Qin, Ling, et al.
Publicado: (2023)

Effectiveness of first and second boost COVID-19 vaccination in healthy adults during BA.5.2/BF.7 surge in China
por: Zhang, Yongchang, et al.
Publicado: (2023)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3eem4jqqgkq90iorag5ejhaqiu